Mechanisms of impaired differentiation in rhabdomyosarcoma

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood, with presumed skeletal muscle origins, because of its myogenic phenotype. RMS is composed of two main subtypes, embryonal RMS (eRMS) and alveolar RMS (aRMS). Whereas eRMS histologically resembles embryonic skeletal muscle, the aRMS subtype is more aggressive and has a poorer prognosis. In addition, whereas the genetic profile of eRMS is not well established, aRMS is commonly associated with distinct chromosome translocations that fuse domains of the transcription factors Pax3 and Pax7 to the forkhead family member FOXO1A. Both eRMS and aRMS tumor cells express myogenic markers such as MyoD, but their ability to complete differentiation is impaired. How this impairment occurs is the subject of this review, which will focus on several themes, including signaling pathways that converge on Pax-forkhead gene targets, alterations in MyoD function, epigenetic modifications of myogenic promoters, and microRNAs whose expression patterns in RMS alter key regulatory circuits to help maintain tumor cells in an opportunistically less differentiated state. Rhabdomyosarcomas (RMS) are the most common soft tissue sarcoma of childhood cancers, which are diagnosed by their associated lineage to skeletal muscle. Although these tumors express terminally differentiation markers, they nevertheless aggressively proliferate and are unable to properly differentiate. In this review, we provide a current overview of the various pathways proposed that when dysregulated contribute to the impaired differentiation of both eRMS and aRMS subtypes. © 2013 FEBS.